Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA.
/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.
AcelRx Pharma (ACRX) Announces Peer-Reviewed Publication On the Use of DSUVIA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative.
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Full year 2020 revenues of $5.4 million compared to $2.3 million in 2019
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results. Last year we achieved many important milestones and objectives that set the foundation for the growth of DSUVIA® in 2021 and beyond, despite the global pandemic, said Vince Angotti, Chief Executive Officer of AcelRx. Like many other companies in our space, COVID has had an impact on the pace of approvals and adoption of DSUVIA as formulary review meetings and elective surgeries have been postponed. However, with vaccine rollouts and elective